Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607550 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
A Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by ArriVent BioPharma.
- Active
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
- 20
- Study locations
NCT05607550: Active Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by ArriVent BioPharma.
NCT05607550 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by ArriVent BioPharma. The registered enrollment target is 398 participants, roughly in line with the 369-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607550, a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by ArriVent BioPharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
- 20
- Study locations
Study Summary
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Conditions Studied
Interventions
- DRUG furmonertinib 240 mg oral, daily
- DRUG furmonertinib 160 mg oral, daily
- DRUG platinum-based chemotherapy
Study Locations (20)
California
- Arrivent Investigative Site - Beverly Hills
- Arrivent Investigative Site - Fullerton
- Arrivent Investigative Site - Long Beach
- Arrivent Investigative Site - Los Alamitos
- Arrivent Investigative Site - Napa
- Arrivent Investigative Site - Orange
- Arrivent Investigative Site - Orange
- Arrivent Investigative site - Sacramento
- Arrivent Investigative Site - San Diego
- Arrivent Investigative Site - Santa Barbara
- Arrivent Investigative Site - Santa Monica
- Arrivent Investigative Site - Santa Rosa
- Arrivent Investigative Site - Whittier
Connecticut
- Arrivent Investigative Site - Hartford
- Arrivent Investigative Site - Norwich
Florida
- Arrivent Investigative Site - Fort Myers
- Arrivent Investigative Site - St. Petersburg
Alabama
- Arrivent Investigative Site - Daphne
Arizona
- Arrivent Investigative Site - Yuma
Arkansas
- Arrivent Investigative Site - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2028-02-15 |
| Phase | Phase 3 |
What the registry record for NCT05607550 still lists
NCT05607550 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 369-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 3 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which furmonertinib 240 mg oral, daily is the first listed.
NCT05607550 names 20 study sites across 6 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT05607550 about?
NCT05607550 is a clinical study titled "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)". Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-sq...
What is the current status of trial NCT05607550?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2023-06-01. Estimated completion is 2028-02-15.
What conditions does trial NCT05607550 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR Exon 20 Mutations.
What interventions are being tested in trial NCT05607550?
The interventions under investigation include: furmonertinib 240 mg oral, daily (DRUG), furmonertinib 160 mg oral, daily (DRUG), platinum-based chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05607550?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607550 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05607550's enrollment target sits among peer trials
398 14th of 31 higher than 18 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RECRUITING · Phase 3
-
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI